MP 112Alternative Names: MP-112
Latest Information Update: 19 Jan 2016
At a glance
- Originator Marathon Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 19 Jan 2016 Discontinued - Phase-III for Huntington's disease in USA (unspecified route)